Home > Products > CD19 & CD3 > Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scIgG)

Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scIgG)  (CAT#: SCIGG-H218)

Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD19 and anti-CD3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
Datasheet INQUIRY

Specifications

Targets
CD19 & CD3
Type
Single chain IgGs
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1
CD19
Gene ID
UniProt ID
Alternative Names
CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Target 2
CD3
Gene ID
UniProt ID
Alternative Names
CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD19 & CD3"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scIgG) (SCIGG-H218). Click the button below to contact us or submit your feedback about this product.